DRTS Stock Performance, Insider Transaction and News

DRTS - Alpha Tau Medical Ltd.

Market Cap	262.55M	P/E	-	EPS this Y	-14.30%	Ern Qtrly Grth	-
Income	-27.63M	Forward P/E	-5.41	EPS next Y	-2.10%	50D Avg Chg	-7.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	2.00%
Dividend	N/A	Price/Book	2.65	EPS next 5Y	-	52W High Chg	-66.00%
Recommedations	1.50	Quick Ratio	11.00	Shares Outstanding	69.92M	52W Low Chg	38.00%
Insider Own	25.63%	ROA	-21.92%	Shares Float	52M	Beta	0.78
Inst Own	2.03%	ROE	-33.17%	Shares Shorted/Prior	40.85K/20.20K	Price	3.79
Gross Margin	-	Profit Margin	-	Avg. Volume	55,037	Target Price	9.25
Oper. Margin	-	Earnings Date	-	Volume	14,894	Change	-2.32%

Healthcare | Biotechnology | Israel

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd. News

12/18/24	Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
12/17/24	Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
12/11/24	Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/06/24	Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
12/01/24	3 Promising Penny Stocks In The US With Market Caps Under $400M
11/19/24	Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/13/24	Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference
11/01/24	Discover Alpha Tau Medical And 2 Other US Penny Stocks
10/21/24	Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
10/11/24	Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment
10/10/24	Alpha Tau Treats First Patient with Recurrent Lung Cancer
09/23/24	FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment
09/20/24	Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
09/17/24	Sidoti Events, LLC's Virtual September Small-Cap Conference
09/03/24	DRTS: Company Seeks to Develop Significant Advance in Cancer Therapy with Alpha DaRT
08/22/24	Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
08/14/24	Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
06/25/24	Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
05/21/24	Alpha Tau to Present at the Jefferies Global Healthcare Conference
05/20/24	Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

DRTS Chatroom

PenkeTrading Posted - 6 hours ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Alpha Tau Medical Ltd. Is that bullish or bearish? $DRTS #RsiOverbought #NASDAQ

Zaneyone Posted - 3 days ago

$XBI $PSTV $DRTS $SLS - Great News for Biotech Investors: Big Pharma is closing its books on 2024 & is in desperate need of new MB$ revenue catalysts. Yes, more M&A is on the way XBI longs! 3 Small cap gems are successfully fighting cancer like PSTV (2 FDA Breakthrough Therapy Designations so far, started sales in Q4) & DRTS (external beam radiation for cancer approved in Israel already) & SLS (a gem). PSTV's Nov. 2024 investor presentation for investors link: https://ir.plustherapeutics.com/static-files/277f59f2-bcfe-4932-8e3d-2f78816aef61 The previous Q2 presentation highlighted 7 recent cases of M&A in the radiotherapy niche most of which were MB$ BO by big pharma. The radiotherapy niche is 1 of the hottest niches for M&A because it's so effective & the results are irrefutable. Link to PSTV's 2025 pipeline: Page 4 (link above). PSTV has $3.9M grant funds incoming, is funded through 2025, and is selling its breakthrough CNSide Assay (3 tests LM, breast & spine cancer) in Q4 for MM$ rev. Big pharma can't resist these 3 small caps strong buy!

AssAndMoney Posted - 4 days ago

$DRTS watching this one

Penger Posted - 1 week ago

$DRTS this the hawk tuai stock ?

Freddie___Mac Posted - 1 week ago

$DRTS hopefully good data... will be a big deal for patients Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day Alpha Tau Medical announced today that an abstract entitled “Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma,” submitted by principal investigators involved in the Company’s Israeli #pancreaticcancer trial, has been accepted to the 2025 #ASCO Gastrointestinal Cancers Symposium, to be held January 23 – 25, 2025 in San Francisco, CA. The poster will be presented during “Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract,” on January 24, 2025 at 11:30am – 1:00pm PT.